Amrecibart

Monoclonal antibody

Also known as REGN9933

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Other / comorbidity
NCT07318610 · Regeneron Pharmaceuticals
2026-07-10 – 2029-11-16 · Peripheral Artery Disease (PAD)
What this study did
NCT07697599 · Regeneron Pharmaceuticals
2026-09-07 – 2029-09-18 · Venous Thromboembolism (VTE)
What this study did
NCT07430956 · Regeneron Pharmaceuticals
2026-04-03 – 2029-06-26 · Atrial Fibrillation (AF)
What this study did
Phase 2 (3)
Other / comorbidity
NCT07175428 · Regeneron Pharmaceuticals
2025-10-20 – 2027-04-21 · Atrial Fibrillation (AF)
What this study did
NCT06299111 · Regeneron Pharmaceuticals
2024-09-20 – 2026-03-27 · Venous Thromboembolism
What this study did
NCT05618808 · Regeneron Pharmaceuticals
2023-05-24 – 2024-05-27 · Venous Thromboembolism
What this study did
Phase 1 (3)
Other / comorbidity
NCT07759167 · Regeneron Pharmaceuticals
2026-09-17 – 2027-04-02 · End-Stage Kidney Disease (ESKD)
What this study did
NCT05102136 · Regeneron Pharmaceuticals
2021-10-27 – 2023-04-04 · Healthy Volunteers
What this study did

Competitive landscape

4 other tracked programmes target this mechanism, 4 of them ahead of this one.

This drug's own stage for Stroke Prevention in Atrial Fibrillation: Stage not on record. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Amrecibart: this drugStage not on recordMonoclonal antibodyFactor XInot yet gradedNo reviewed efficacy summary in this indication
Cenvacibart
Phase 3(overall)
Monoclonal antibodyFactor XI
not yet graded(overall)
No reviewed efficacy summary in this indication
SHR-2004
Phase 3(overall)
UndisclosedFactor XI
not yet graded(overall)
No reviewed efficacy summary in this indication
Gruticibart
Phase 2(overall)
Monoclonal antibodyFactor XI
Partial signal(overall)
No reviewed efficacy summary in this indication
SRSD107
Phase 2(overall)
RNA / oligonucleotideFactor XI
not yet graded(overall)
No reviewed efficacy summary in this indication
Milvexian
Phase 1(overall)
Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Abelacimab
—(overall)
Monoclonal antibodyFactor XI/XIa (FXI/FXIa)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Amrecibart to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
February 2027 (1)
Phase 2Atrial Fibrillation (AF)Recruiting
Est. primary completion 2027-02-09 · NCT07175428 · CT.gov ↗
What to watch
April 2027 (1)
Phase 1End-Stage Kidney Disease (ESKD)Recruiting
Est. primary completion 2027-04-02 · NCT07759167 · CT.gov ↗
What to watch
2029 (3)
March 2029 (1)
Phase 3Atrial Fibrillation (AF)Recruiting
Est. primary completion 2029-03-28 · NCT07430956 · CT.gov ↗
What to watch
June 2029 (1)
Phase 3Venous Thromboembolism (VTE)Recruiting
Est. primary completion 2029-06-25 · NCT07697599 · CT.gov ↗
What to watch
August 2029 (1)
Phase 3Peripheral Artery Disease (PAD)Recruiting
Est. primary completion 2029-08-18 · NCT07318610 · CT.gov ↗
What to watch

See the full readout calendar ↗